Wegovy® injection becomes first GLP-1 weight-loss treatment approved for 48-hour controlled-temperature delivery in the EU
Novo Nordisk A/S The European Medicines Agency (EMA) has approved an update to the product information of Wegovy®…
Wegovy® injection becomes first GLP-1 weight-loss treatment approved for 48-hour controlled-temperature delivery in the EU
Novo Nordisk A/S The European Medicines Agency (EMA) has approved an update to the product information of Wegovy®…
Novo Nordisk’s Wegovy® HD available now nationwide
Wegovy® HD available through 70,000+ US pharmacies, NovoCare® Pharmacy, select telehealth providers, and more Wegovy® HD further expands the offerings…
FDA approves Novo Nordisk’s new Wegovy® HD injection, delivering the highest weight loss to date for a Wegovy® injection, adding to its already expansive clinical profile
Average weight loss of ~21% at 72 weeks in adults with obesity if all patients stayed on treatment*…
FDA approves Novo Nordisk’s new Wegovy® HD injection, delivering the highest weight loss to date for a Wegovy® injection, adding to its already expansive clinical profile
Average weight loss of ~21% at 72 weeks in adults with obesity if all patients stayed on treatment*…